InvestorsObserver is giving BioCardia Inc (BCDA) an Analyst Rating Rank of 80, meaning BCDA is ranked higher by analysts than 80% of stocks. The average projection by analysts for BCDA is $18.333 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With BioCardia Inc Stock Today?
BioCardia Inc (BCDA) stock has fallen -5.34% while the S&P 500 has risen 1.47% as of 2:21 PM on Wednesday, Aug 12. BCDA has fallen -$0.14 from the previous closing price of $2.62 on volume of 122,275 shares. Over the past year the S&P 500 is up 15.59% while BCDA has fallen -47.68%. BCDA lost -$2.59 per share the over the last 12 months.
